Moreover, rpFVIII demonstrates markedly lower cross-reactivity with human anti-FVIII inhibitors [30,31,32], making it a safer and more targeted therapeutic option in patients with AHA [33]. This evidence concerns the gene F8 and autoimmune hemolytic anemia.